Liothyronine sodium

碘塞罗宁钠

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameLiothyronine sodium
Drug Alias Name三碘代甲状腺素钠盐Triiodothyronine sodium碘甲腺氨酸钠Sustained-release liothyronine sodiumSustained-release T3 +[19] 
ClassificationSmall molecules > Amino acid supplement, Lipids and Vitamins
Mechanisms of ActionThyroid hormone receptor beta-1 agonistsThyroid hormone receptor alpha agonists
TargetsThyroid hormone receptor betaThyroid hormone receptor alpha
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)HypothyroidismObesity +[13] 
Global Approved IndicationsHypothyroidism
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1956/05/08
Country/TerritoryUnited StatesGreece
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesUc San FranciscoKing Pharmaceuticals Inc
Inactive CompaniesOregon Health And Science UniversityJohns Hopkins UniversityNational Cancer Institute +[7] 
Active IndicationsHypothyroidismMedulloblastoma
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)ObesityInsulin Resistance +[11] 

Other Information

ATC CodeH03AA02
Related LinksWikipediaDrugBankKEGG